Gamma Knife radiosurgery for intracranial hemangioblastoma

@article{Silva2016GammaKR,
  title={Gamma Knife radiosurgery for intracranial hemangioblastoma},
  author={Danilo Silva and Mathew M. Grabowski and Rupa G. Juthani and Mayur Sharma and Lilyana Angelov and Michael A. Vogelbaum and Samuel T. Chao and John H. Suh and Alireza M. Mohammadi and Gene H. Barnett},
  journal={Journal of Clinical Neuroscience},
  year={2016},
  volume={31},
  pages={147-151}
}

Gamma Knife Stereotactic Radiosurgery favorably changes the clinical course of hemangioblastoma growth in von Hippel-Lindau and sporadic patients

GKRS is a successful long-term treatment option for hemangioblastomas changing the clinical course from saltatory growth to reduction in tumor volume.

Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis

Multiple studies show excellent tumor control at 5-year follow up, however, the long-term efficacy of SRS for CNS hemangioblastomas still needs to be investigated, and the studies exploring the role of S RS for early treatment of asymptomatic lesions is wanting.

Intracranial hemangioblastoma – A SEER-based analysis 2004–2013

Clinical factors such as younger age, Caucasian race, and presence of surgery are significant independent factors for overall survival in patients with HBs, though analysis regarding extent of surgery did not produce a meaningful relationship.

Glioblastoma de células gigantes: informe de un caso

Antecedentes: El Glioblastoma (GB) o astrocitoma grado IV, es un tumor agresivo que se origina de células gliales, con alto grado de malignidad, prevalencia menor al 1% en fosa posterior e incidencia

References

SHOWING 1-10 OF 22 REFERENCES

THE ROLE OF STEREOTACTIC RADIOSURGERY FOR INTRACRANIAL HEMANGIOBLASTOMAS

SRS is an important tool in the management of hemangioblastomas and is associated with a high tumor control rate and a low risk of adverse radiation effects, as well as factors associated with an improved progression-free survival.

The clinical outcome of intracranial hemangioblastomas treated with linac-based stereotactic radiosurgery and radiotherapy

There was a trend toward local failure only in cystic tumors, but this trend was not found to be statistically significant and SRS/SRT achieved a high local control rate in intracranial hemangioblastomas without radiation-induced complications.

Gamma knife surgery for hemangioblastomas.

Gamma knife surgery is a safe and effective method to control hemangioblastomas for as many as 10 years and peritumoral contrast enhancement may be seen in larger tumors.

The long-term outcomes of radiosurgery for intracranial hemangioblastomas.

SRS could be offered as an effective treatment for small, solid, and VHL-associated HBs if the tumors show apparent enlargement in size or can possibly become symptomatic along with a slight increase in size, SRS should be recommended before they present with the clinical symptoms.

Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study.

When either sporadic or VHL-associated hemangioblastomas were observed to grow on serial imaging studies, SRS provided tumor control in 79%-92% of tumors.

Stereotactic Radiosurgery for Hemangioblastomas of the Brain

For small to moderate size hemangioblastomas, multiple or recurrent tumors, and for patients who are not surgical candidates, radiosurgery is a safe and effective option to control disease and improve survival.

Gamma knife surgery for multiple hemangioblastomas.

To achieve tumor control and avoid morbidity, the surgeon should keep in mind minimizing field overlapping by using a small-diameter collimator or applying a steep dose gradient, and by accurate dose prescription.

Gamma knife radiosurgery for intracranial haemangioblastomas

Gamma knife radiosurgery is effective for solid type tumours, even if the marginal dose is relatively low, and surgical removal is recommended for mural nodule with cyst type tumour tumour types, when possible.

Radiosurgery for hemangioblastoma: results of a multiinstitutional experience.